BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1395 related articles for article (PubMed ID: 16644314)

  • 41. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease.
    Vaverkova H; Farnier M; Averna M; Missault L; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Brudi P
    Clin Biochem; 2011 Jun; 44(8-9):627-34. PubMed ID: 21349260
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
    Wlodarczyk J; Sullivan D; Smith M
    Am J Cardiol; 2008 Dec; 102(12):1654-62. PubMed ID: 19064019
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
    Bergheanu SC; Van Tol A; Dallinga-Thie GM; Liem A; Dunselman PH; Van der Bom JG; Jukema JW
    Curr Med Res Opin; 2007 Sep; 23(9):2235-40. PubMed ID: 17692153
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
    Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
    Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
    Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
    Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
    Deedwania PC; Hunninghake DB; Bays HE; Jones PH; Cain VA; Blasetto JW;
    Am J Cardiol; 2005 Feb; 95(3):360-6. PubMed ID: 15670545
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
    Hunninghake D; Bakker-Arkema RG; Wigand JP; Drehobl M; Schrott H; Early JL; Abdallah P; McBride S; Black DM
    J Fam Pract; 1998 Nov; 47(5):349-56. PubMed ID: 9834769
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study.
    Idris I; Tate H; Ahmad A; McCormack T
    J Clin Lipidol; 2011; 5(4):316-23. PubMed ID: 21784378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rosuvastatin in the management of hyperlipidemia.
    Cheng JW
    Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
    Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expanding options with a wider range of rosuvastatin doses.
    Olsson AG
    Clin Ther; 2006 Nov; 28(11):1747-63. PubMed ID: 17212997
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
    Shioji K; Izuhara M; Mitsuoka H; Uegaito T; Matsuda M;
    Cardiovasc Ther; 2014 Jun; 32(3):97-104. PubMed ID: 24456217
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
    Wolffenbuttel BH; Franken AA; Vincent HH;
    J Intern Med; 2005 Jun; 257(6):531-9. PubMed ID: 15910557
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
    Barrios V; Amabile N; Paganelli F; Chen JW; Allen C; Johnson-Levonas AO; Massaad R; Vandormael K
    Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
    Miller PS; Smith DG; Jones P
    Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolaemia: the first Indian study.
    Jayaram S; Jain MM; Naikawadi AA; Gawde A; Desai A
    J Indian Med Assoc; 2004 Jan; 102(1):48-50, 52. PubMed ID: 15195867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
    Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 70.